false
0001689375
0001689375
2023-11-22
2023-11-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 22, 2023
ENTRADA THERAPEUTICS, INC.
(Exact name of registrant as specified in its
charter)
| Delaware |
001-40969 |
81-3983399 |
| (State or other jurisdiction |
(Commission |
(I.R.S. Employer |
| of incorporation) |
File Number) |
Identification No.) |
One Design Center Place
Suite 17-500
|
|
|
| Boston, MA |
|
02210 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area
code: (857) 520-9158
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Stock, $0.0001 par value per share |
|
TRDA |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On November 22, 2023, Entrada Therapeutics, Inc.
(the “Company”) issued a press release providing an update on ENTR-601-44, its lead product candidate that is being developed
for patients with Duchenne muscular dystrophy. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 7.01 of this Form 8-K
(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 8.01. Other Events.
Update on ENTR-601-44
On November 22, 2023, the Company provided an update on ENTR-601-44,
its lead product candidate that is being developed for patients with Duchenne muscular dystrophy.
The Company announced the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.
The Company plans to announce data from ENTR-601-44-101 in the second half of 2024.
The primary objective of the Company’s double-blind, single ascending
dose Phase 1 clinical trial, which is expected to enroll approximately 40 participants, is to evaluate the safety and tolerability of
a single dose of ENTR-601-44 in healthy male volunteers. ENTR-601-44-101 will also evaluate pharmacokinetics and target engagement, as
measured by exon skipping in the skeletal muscle.
Update on ENTR-601-44 Investigational New Drug (“IND”)
Application
The Company was previously notified by the FDA (“FDA” or
the “Agency”) that the IND for the Phase 1 clinical trial of ENTR-601-44 had been placed on clinical hold. Despite providing
additional information to the FDA, the Company was informed that the Agency declined to lift the clinical hold. Importantly, the information
that was submitted to the FDA supported the initiation of the Phase 1 clinical trial in the United Kingdom in September 2023.
Forward-Looking Statements
This Form 8-K contains forward-looking statements
that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form 8-K,
including statements regarding the Company’s strategy, future operations, prospects and plans, objectives of management, the Company’s
ability to continue to recruit for and complete its ENTR-601-44-101 Phase 1 clinical trial in the United Kingdom, expectations regarding
the announcement of data from its ENTR-601-44-101 clinical trial in the second half of 2024, express or implied statements regarding the
clinical hold on the IND for ENTR-601-44, the Company’s ability to address the FDA’s concerns regarding ENTR-601-44, the Company’s
ability to initiate and recruit for potential global clinical trials for ENTR-601-44 in patients with Duchenne muscular dystrophy (DMD)
who are exon 44 skipping amenable, expectations regarding the safety and therapeutic benefits of ENTR-601-44, and the continued development
and advancement of ENTR-601-44, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act
of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,”
“predict,” “project,” “potential,” “should,” or “would,” or the negative of
these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including:
uncertainties inherent in the identification and development of product candidates, including the conduct of research activities and the
initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from
preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory clearance for INDs
or equivalent foreign applications and initiate or complete clinical trials; whether results from preclinical studies will be predictive
of the results of later preclinical studies and clinical trials; whether the Company’s cash resources will be sufficient to fund
the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties
identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s
most recent Form 10-K and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included
in this Form 8-K represent the Company’s views as of the date of this Form 8-K. The Company anticipates that subsequent
events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date of this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Entrada Therapeutics, Inc. |
| |
|
| Date: November 22, 2023 |
By: |
/s/ Dipal Doshi |
| |
|
Dipal Doshi |
| |
|
President and Chief Executive Officer |
Exhibit 99.1
Entrada Therapeutics Announces Updates on ENTR-601-44
in Duchenne Muscular Dystrophy
– Company completes dosing of first and
second cohorts in Phase 1 clinical trial, ENTR-601-44-101 –
– ENTR-601-44 clinical development program
remains on track with data readout expected in second half of 2024 –
– U.S. FDA clinical hold on IND application
remains in effect –
– Cash runway expected through 2025 –
Boston, November 22, 2023 – Entrada Therapeutics, Inc.
(Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal
Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the completion of dosing for the first and second
cohorts of its Phase 1 clinical trial, ENTR-601-44-101. Entrada plans to announce data from ENTR-601-44-101 in the second half of 2024.
“Our strategy has always been to run a single Phase 1 clinical
trial for ENTR-601-44 and, notably, that trial is progressing in the United Kingdom. We are pleased to have completed dosing of the first
and second cohorts of participants,” said Dipal Doshi, President and Chief Executive Officer at Entrada Therapeutics. “In
parallel with the Phase 1 clinical trial, we continue to plan for the global development of ENTR-601-44 which will include clinical trials
in patients with Duchenne who are exon 44 skipping amenable.”
The primary objective of Entrada’s double-blind, single ascending
dose Phase 1 clinical trial, which is expected to enroll approximately 40 participants, is to evaluate the safety and tolerability of
a single dose of ENTR-601-44 in healthy male volunteers. ENTR-601-44-101 will also evaluate pharmacokinetics and target engagement, as
measured by exon skipping in the skeletal muscle.
Update on ENTR-601-44 Investigational New Drug (IND) Application
Entrada was previously notified by the FDA that the IND for the Phase
1 clinical trial of ENTR-601-44 had been placed on clinical hold. Despite providing additional information to the FDA, the Company was
informed that the Agency declined to lift the clinical hold. Importantly, the information that was submitted to the FDA supported the
initiation of the Phase 1 clinical trial in the United Kingdom in September 2023.
“We are disappointed that the U.S. clinical hold has not been
lifted, especially given the strength of the data package submitted to the FDA. It’s important to emphasize that the ongoing ENTR-601-44
development program continues to progress, with ENTR-601-44-101 clinical data expected in the second half of 2024. We will re-engage the
FDA to discuss next steps in due course,” concluded Mr. Doshi.
About ENTR-601-44
ENTR-601-44, a proprietary Endosomal Escape Vehicle
(EEV™)-conjugated phosphorodiamidate morpholino oligomer (PMO), is the lead product candidate within Entrada’s Duchenne
muscular dystrophy franchise from its growing pipeline of EEV-therapeutics. Each EEV-PMO therapeutic candidate has an
oligonucleotide sequence designed and optimized for the specific subpopulation of interest. ENTR-601-44 is designed to address the
underlying cause of Duchenne due to mutated or missing exons in the DMD gene. ENTR-601-44, an investigational therapy for the
potential treatment of people living with Duchenne who are exon 44 skipping amenable, is being evaluated for its potential to
restore the mRNA reading frame and allow for the translation of dystrophin protein that is slightly shortened but still
functional.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming
to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage
intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to
enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved
therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio
of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases,
among others. The Company’s lead oligonucleotide programs include ENTR-601-44, ENTR-601-45 and ENTR-601-50 for the potential treatment
of people living with Duchenne who are exon 44, 45 and 50 skipping amenable, respectively, as well as our partnered candidate ENTR-701
for myotonic dystrophy type 1.
For more information about Entrada, please
visit our website, www.entradatx.com, and follow us on LinkedIn.
Forward-Looking Statements
This
news release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this news release, including statements regarding Entrada’s strategy, future
operations, prospects and plans, objectives of management, Entrada’s ability to continue to recruit for and complete its
ENTR-601-44-101 Phase 1 clinical trial in the United Kingdom, expectations regarding the
announcement of data from its ENTR-601-44-101 clinical trial in the second half of 2024, express
or implied statements regarding the clinical hold on the IND for ENTR-601-44, Entrada’s ability to address the FDA’s
concerns regarding ENTR-601-44, Entrada’s ability to initiate and recruit for potential
global clinical trials for ENTR-601-44 in patients with Duchenne muscular dystrophy (DMD) who are exon 44 skipping amenable,
expectations regarding the safety and therapeutic benefits of ENTR-601-44, the continued
development and advancement of ENTR-601-44, ENTR-601-45 and ENTR-601-50 for the treatment of DMD, and ENTR-701 for the treatment of
myotonic dystrophy type 1 (DM1), the ability to develop additional therapeutic programs, including further exon skipping programs,
the potential therapeutic benefits of its EEV candidates, and the sufficiency of its cash resources through 2025, constitute
forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “objective,” “ongoing,”
“plan,” “predict,” “project,” “potential,” “should,” or
“would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. Entrada may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed
in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the
identification and development of product candidates, including the conduct of research activities and the initiation and completion
of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and
clinical trials; the timing of and Entrada’s ability to submit and obtain regulatory clearance for INDs or equivalent foreign
applications and initiate or complete clinical trials; whether results from preclinical studies will be predictive of the results of
later preclinical studies and clinical trials; whether Entrada’s cash resources will be sufficient to fund the Company’s
foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties
identified in Entrada’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent
Form 10-K and in subsequent filings Entrada may make with the SEC. In addition, the forward-looking statements included in this
news release represent Entrada’s views as of the date of this news release. Entrada anticipates that subsequent events and
developments will cause its views to change. However, while Entrada may elect to update these forward-looking statements at some
point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon
as representing Entrada’s views as of any date subsequent to the date of this news release.
Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com
v3.23.3
Cover
|
Nov. 22, 2023 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Nov. 22, 2023
|
| Entity File Number |
001-40969
|
| Entity Registrant Name |
ENTRADA THERAPEUTICS, INC.
|
| Entity Central Index Key |
0001689375
|
| Entity Tax Identification Number |
81-3983399
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
One Design Center Place
|
| Entity Address, Address Line Two |
Suite 17-500
|
| Entity Address, City or Town |
Boston
|
| Entity Address, State or Province |
MA
|
| Entity Address, Postal Zip Code |
02210
|
| City Area Code |
857
|
| Local Phone Number |
520-9158
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, $0.0001 par value per share
|
| Trading Symbol |
TRDA
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
true
|
| Elected Not To Use the Extended Transition Period |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2024 to May 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From May 2023 to May 2024
